<DOC>
	<DOCNO>NCT00774397</DOCNO>
	<brief_summary>The objective investigate antiviral effect , safety , pharmacokinetics BI 201335 ( Faldaprevir ) , give soft gelatine capsule , patient hepatitis C virus ( HCV ) genotype 1 infection . Combination therapy BI 201335 ( Faldaprevir ) pegylated interferon α-2a ( PegIFN ) ribavirin ( RBV ) , without 3-day lead-in , assess treatment-naïve ( TN ) treatment experience ( TE ) patient .</brief_summary>
	<brief_title>Antiviral Effect , Safety , Pharmacokinetics BI201335 +PegIFN/RBV HCV-GT1 ( SILEN-C1 &amp; 2 )</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Inclusion criterion : chronic HCV GT1 ; therapynaive IFN , PegIFN , RBV ; HCV VL &gt; =100,000 IU/mL Liver biopsy within 2 year prior study enrolment show necroinflammatory activity presence fibrosis Normal retinal finding fundoscopy within 6 month prior Day 1 age 1865 year Females male adequate contraception Exclusion criterion : Mixed genotype ( 1/2 , 1/3 , 1/4 ) , diagnose genotypic test screen Previous treatment protease inhibitor Evidence liver disease due cause chronic HCV infection HIV1 HIV2 positive HBV positive Decompensated liver disease , history decompensated liver disease Active suspect malignancy history malignancy within last 5 year History alcohol drug abuse within past 12 month . Usage investigational drug within 30 day prior enrolment , 5 halflives , whichever long Known hypersensitivity ingredient study drug Condition define one opinion investigator may put patient risk participation study may influence result study patient 's ability participate study Alphafetoprotein value &gt; 100ng/mL screening ; &gt; 20ng/mL &lt; =100ng/mL , patient include evidence liver cancer two congruent image study Total bilirubin &gt; 1.5x ULN wiht ratio direct/indirect &gt; 1 . ALT AST level &gt; 5x ULN INR prolong &gt; 1.5x ULN Exclusion criterion related PegIFN and/or RBV restriction .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>